Willerson, James T.

Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein

Ridker, P. M., Danielson, E., Fonseca, F. A. H., Genest, J., Gotto, A. M., Kastelein, J. J. P., Koenig, W., Libby, P., Lorenzatti, A. J., MacFadyen, J. G., et al. (2008) · New England Journal of Medicine

Lipoproteins and Cardiovascular HealthAtherosclerosis and Cardiovascular Diseases

Cited by 6,674

Circadian Variation in the Frequency of Onset of Acute Myocardial Infarction

Muller, J. E., Stone, P. H., Turi, Z. G., Rutherford, J. D., Czeisler, C. A., Parker, C., Poole, W. K., Passamani, E., Roberts, R., Robertson, T., et al. (1985) · New England Journal of Medicine

Acute Myocardial Infarction ResearchCircadian rhythm and melatonin

Cited by 1,884

Randomized, Double-Blind, Placebo-Controlled, Pilot Trial of Infliximab, a Chimeric Monoclonal Antibody to Tumor Necrosis Factor-α, in Patients With Moderate-to-Severe Heart Failure: Results of the Anti-TNF Therapy Against Congestive Heart failure (ATTACH) Trial

Chung, E. S., Packer, M., Lo, K. H., Fasanmade, A. A., & Willerson, J. T. (2003) · Circulation

Heart Failure Treatment and ManagementCardiac Fibrosis and Remodeling

Cited by 1,644

Inflammation as a Cardiovascular Risk Factor

Willerson, J. T., & Ridker, P. M. (2004) · Circulation

Lipoproteins and Cardiovascular HealthAtherosclerosis and Cardiovascular Diseases

Cited by 1,304

Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial

Ridker, P. M., Danielson, E., Fonseca, F. A., Genest, J., Gotto, A. M., Kastelein, J. J., Koenig, W., Libby, P., Lorenzatti, A. J., MacFadyen, J. G., et al. (2009) · The Lancet

Lipoproteins and Cardiovascular HealthCancer, Lipids, and Metabolism

Cited by 1,010

Hippo signaling impedes adult heart regeneration

Heallen, T., Morikawa, Y., Leach, J., Tao, G., Willerson, J. T., Johnson, R. L., & Martin, J. F. (2013) · Development

Congenital heart defects researchHippo pathway signaling and YAP/TAZ

Cited by 458

Coming of Age of C-Reactive Protein: Using Inflammation Markers in Cardiology

Yeh, E. T. H., & Willerson, J. T. (2003) · Circulation

Biomarkers in Disease MechanismsLipoproteins and Cardiovascular Health

Cited by 403

The Hippo Pathway Is Activated and Is a Causal Mechanism for Adipogenesis in Arrhythmogenic Cardiomyopathy

Chen, S. N., Gurha, P., Lombardi, R., Ruggiero, A., Willerson, J. T., & Marian, A. J. (2014) · Circulation Research

Hippo pathway signaling and YAP/TAZCardiomyopathy and Myosin Studies

Cited by 275

Difference in Patient Profiles and Outcomes in Japanese Versus American Patients Undergoing Coronary Revascularization (Collaborative Study by CREDO-Kyoto and the Texas Heart Institute Research Database)

Kohsaka, S., Kimura, T., Goto, M., Lee, V.-V., Elayda, M., Furukawa, Y., Fukushima, M., Komeda, M., Sakata, R., Willerson, J. T., et al. (2010) · The American Journal of Cardiology

Coronary Interventions and DiagnosticsCardiac and Coronary Surgery Techniques

Cited by 60